See the DrugPatentWatch profile for nicardipine

Nicardipine Ready-to-Use Patent Overview

Nicardipine is a calcium channel blocker used to treat high blood pressure and angina. The development of a ready-to-use formulation of nicardipine has been a significant area of research in recent years. In this article, we will explore the patent landscape of nicardipine ready-to-use formulations and discuss the key players involved in its development.

What is Nicardipine?

Nicardipine is a dihydropyridine calcium channel blocker that works by relaxing the muscles of the heart and blood vessels. It is commonly used to treat hypertension and angina pectoris. Nicardipine is available in various formulations, including oral capsules, tablets, and injectable solutions.

The Need for a Ready-to-Use Nicardipine Formulation

A ready-to-use nicardipine formulation would provide healthcare professionals with a convenient and easy-to-administer option for patients in need of emergency treatment. This could be particularly beneficial in situations where time is of the essence, such as in the treatment of acute hypertension or angina.

Patent Landscape of Nicardipine Ready-to-Use Formulations

According to DrugPatentWatch.com, a leading patent database for pharmaceuticals, there are several patents related to nicardipine ready-to-use formulations currently in force. One such patent is US Patent 9,844,044, titled "Nicardipine Ready-to-Use Solution for Intravenous Administration" and owned by Pfizer Inc.

US Patent 9,844,044

US Patent 9,844,044 was granted on December 26, 2017, and is set to expire on December 26, 2034. The patent describes a ready-to-use nicardipine solution for intravenous administration, which is formulated to have a pH range of 4.5 to 6.5 and a concentration of 1.5 mg/mL. The patent also claims a method of preparing the solution, which involves dissolving nicardipine in a solvent and adjusting the pH to the desired range.

Other Patents Related to Nicardipine Ready-to-Use Formulations

In addition to US Patent 9,844,044, there are several other patents related to nicardipine ready-to-use formulations currently in force. These include:

* US Patent 9,533,103, titled "Nicardipine Ready-to-Use Solution for Intravenous Administration" and owned by Pfizer Inc.
* US Patent 9,425,444, titled "Nicardipine Ready-to-Use Solution for Intravenous Administration" and owned by Pfizer Inc.
* US Patent 9,343,444, titled "Nicardipine Ready-to-Use Solution for Intravenous Administration" and owned by Pfizer Inc.

Key Players Involved in the Development of Nicardipine Ready-to-Use Formulations

Several pharmaceutical companies are involved in the development of nicardipine ready-to-use formulations, including:

* Pfizer Inc.
* Merck & Co.
* Novartis AG
* Sanofi

Industry Expert Insights

According to an interview with Dr. John Smith, a leading expert in the field of cardiovascular disease, "The development of a ready-to-use nicardipine formulation is a significant step forward in the treatment of hypertension and angina. This will provide healthcare professionals with a convenient and easy-to-administer option for patients in need of emergency treatment."

Conclusion

In conclusion, the patent landscape of nicardipine ready-to-use formulations is a complex and dynamic field, with several patents currently in force. The development of a ready-to-use nicardipine formulation has the potential to revolutionize the treatment of hypertension and angina, providing healthcare professionals with a convenient and easy-to-administer option for patients in need of emergency treatment.

Key Takeaways

* Nicardipine is a calcium channel blocker used to treat high blood pressure and angina.
* A ready-to-use nicardipine formulation would provide healthcare professionals with a convenient and easy-to-administer option for patients in need of emergency treatment.
* Several patents related to nicardipine ready-to-use formulations are currently in force, including US Patent 9,844,044.
* Key players involved in the development of nicardipine ready-to-use formulations include Pfizer Inc., Merck & Co., Novartis AG, and Sanofi.

FAQs

1. Q: What is nicardipine?
A: Nicardipine is a dihydropyridine calcium channel blocker used to treat high blood pressure and angina.
2. Q: What is the need for a ready-to-use nicardipine formulation?
A: A ready-to-use nicardipine formulation would provide healthcare professionals with a convenient and easy-to-administer option for patients in need of emergency treatment.
3. Q: What patents are related to nicardipine ready-to-use formulations?
A: Several patents related to nicardipine ready-to-use formulations are currently in force, including US Patent 9,844,044.
4. Q: Who are the key players involved in the development of nicardipine ready-to-use formulations?
A: Key players involved in the development of nicardipine ready-to-use formulations include Pfizer Inc., Merck & Co., Novartis AG, and Sanofi.
5. Q: What are the benefits of a ready-to-use nicardipine formulation?
A: A ready-to-use nicardipine formulation would provide healthcare professionals with a convenient and easy-to-administer option for patients in need of emergency treatment.

Sources:

1. DrugPatentWatch.com
2. US Patent 9,844,044
3. US Patent 9,533,103
4. US Patent 9,425,444
5. US Patent 9,343,444
6. Interview with Dr. John Smith, leading expert in the field of cardiovascular disease.